Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

IREN is drawing attention amid a sharp selloff in AI neocloud stocks, fueled by Elon Musks warning of industry failures and consolidation alongside broader concerns about debt and data-center financing. Traders are divided between fears that capital constraints could threaten the business and claims that the selling is sector-wide FUD, with bulls pointing to IRENs contracts and infrastructure as reasons to buy the dip.

Elon Musks warning that neocloud providers face tighter debt access and industry consolidation has fueled concern about Nebius and its peers. Traders debate whether Nebius is exposed to those risks, with bulls pointing to its recent financing and managements statement that it has enough funding for planned expansion.

Nus strong quarterly results, including record profitability and continued growth, have fueled a share-price rebound. Traders are split between viewing the results as evidence of a strong business and expecting profit-taking, with some frustrated that solid fundamentals have not led to sustained gains.

Modernas positive Phase 3 melanoma-vaccine results with Mercks Keytrudashowing reduced recurrence or deathhave driven a sharp debate after the stocks selloff. Bulls see validation of a broader cancer-vaccine platform, while skeptics question whether the benefit, commercial prospects, and data beyond melanoma justify the expectations built into the rally.

Lulas election victory over Bolsonaro has prompted a sharp repricing of Brazilian stocks, with traders concerned about political uncertainty and Petrobrass state ownership and dividend outlook. The community is split between sellers who see further risk and investors treating the selloff as a buying opportunity, citing the companys oil business and dividends.

Lulas unexpected election victory over Bolsonaro has driven a sharp selloff in Brazilian assets, with traders citing uncertainty over economic policy and the markets prior preference for Bolsonaro. Some see the decline as a buying opportunity, while others expect further weakness.

Attention centers on SELLASs event-driven Phase 3 REGAL trial of its GPS leukemia vaccine: traders are watching for the 80th survival event and the subsequent final analysis, with the last disclosed count at 78. Bulls interpret the prolonged wait as a possible sign of extended survival, while skeptics say the delay and company silence do not establish efficacy; speculation that results may be timed around ASH or a potential deal remains unconfirmed.

AVT is drawing attention amid a volatile rebound, with traders focused on breakout levels and whether buying activity can overcome thin liquidity and sell walls. Aventus Clouds decentralized-compute and appchain updates add a bullish project narrative, while others warn that concentrated holdings and inconsistent demand make the move speculative.

Visa is drawing attention ahead of its fiscal fourth-quarter and full-year report, with traders focused on the outlookparticularly marginsand how the stock reacts after the release. Bulls point to its strength near record highs, while skeptics say expectations may be priced in and warn that soft guidance could prompt a pullback.

Amgens IMDELLTRA-and-IMFINZI combination showed a substantial survival benefit in a Phase 3 trial for extensive-stage small-cell lung cancer, prompting traders to discuss the drugs potential as a growth driver. The reaction is broadly optimistic, with some attention also on Repathas sales growth and the stocks recent run.